Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
2 clusters · 4 sources · 18 days · First seen · Last updated
US federal marijuana rescheduling legal proceedings
Overview
The federal process to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act has encountered administrative and legal delays.
In late September 2026, Chief Administrative Law Judge Derek C. Julius issued a stay in the rescheduling case. This pause was intended to allow for the consideration of a Government Accountability Office (GAO) report, which identified deficiencies in federal drug-scheduling procedures. Specifically, the audit noted that the DEA lacks clear policies regarding staff roles and the FDA lacks written procedures for conducting evaluations or developing scheduling recommendations.
By mid-October 2026, the rescheduling process remained stalled as the DOJ and DEA addressed requests for briefings on the GAO report. While an executive order issued in December 2025 aimed to expedite the reclassification of FDA-approved and state-licensed medical marijuana, final orders from the DEA have not yet been issued. Analysts suggest a resolution may not occur until late 2026 or early 2027.
Entities
Drug Enforcement Administration · Department of Justice · Food and Drug Administration · Trulieve Cannabis Corp. · Donald Trump
Timeline
-
[BUSINESS] 2 sourcesDEA marijuana rescheduling process faces administrative delays
The federal rescheduling of marijuana to Schedule III faces delays due to DEA administrative stays, impacting industry players like Canopy Growth despite previous executive orders to expedite the process.
-
[POLITICS] 2 sourcesDEA judge stays marijuana rescheduling case pending GAO report review
A federal judge has stayed the marijuana rescheduling case until October 13 to consider adding a GAO report regarding deficiencies in DEA and FDA drug-scheduling procedures to the record.
Sources
cannabislaw.report · mugglehead.com · theascent.com · themarijuanaherald.com